SATSUMA PHARMACEUTICALS
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
SATSUMA PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.satsumarx.com
Total Employee:
1+
Status:
Active
Contact:
650.410.3200
Total Funding:
154 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company utilizing proprietary technology to develop novel therapies.
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Commodore Capital
Commodore Capital investment in Post-IPO Equity - Satsuma Pharmaceuticals
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Satsuma Pharmaceuticals
Shin Nippon Biomedical Laboratories (SNBL)
Shin Nippon Biomedical Laboratories (SNBL) investment in Post-IPO Equity - Satsuma Pharmaceuticals
Logos Capital
Logos Capital investment in Post-IPO Equity - Satsuma Pharmaceuticals
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Satsuma Pharmaceuticals
Aspire Capital Partners LLC
Aspire Capital Partners LLC investment in Post-IPO Equity - Satsuma Pharmaceuticals
Vivo Capital
Vivo Capital investment in Post-IPO Equity - Satsuma Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Satsuma Pharmaceuticals
Point72
Point72 investment in Post-IPO Equity - Satsuma Pharmaceuticals
Ghost Tree Capital Group
Ghost Tree Capital Group investment in Post-IPO Equity - Satsuma Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2020-03-05 | Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer |
Official Site Inspections
http://www.satsumarx.com Semrush global rank: 7.43 M Semrush visits lastest month: 498
- Host name: 37.172.196.104.bc.googleusercontent.com
- IP address: 104.196.172.37
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Satsuma Pharmaceuticals"
About Us | Satsuma Pharmaceuticals
Leadership | Satsuma Pharmaceuticals
Shannon began her career through a drug development fellowship with Cato Research, a specialty contract research organization, and then transitioned into medical writing and …See details»
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug …
Oct 31, 2024 For further information, please visit www.satsumarx.com. About SNBL Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research organization …See details»
EX-99.1 - SEC.gov
Apr 17, 2023 A free copy of the Tender Offer Statement and the Schedule 14D-9 Solicitation Statement will also be made available to all stockholders of Satsuma by contacting Satsuma at …See details»
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug
Oct 31, 2024 For further information, please visit www.satsumarx.com. About SNBL Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research organization …See details»
Satsuma Pharmaceuticals and SNBL Announce Publication of
Oct 8, 2024 For further information, please visit www.satsumarx.com. About SNBL. Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) (TSE:2395) is a listed contract research organization …See details»
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug …
Oct 31, 2024 For further information, please visit www.satsumarx.com. About SNBL. Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research …See details»
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug
Oct 31, 2024 For further information, please visit www.satsumarx.com. About SNBL. Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) (TSE:2395) is a listed contract research …See details»
SNBL to Acquire Satsuma Pharmaceuticals - Yahoo Finance
Apr 16, 2023 Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share …See details»
About | Satsuma Pharmaceuticals
©2024 Satsuma Pharmaceuticals, Inc. All Rights Reserved. | Terms of Use | Privacy PolicySee details»
Satsuma Pharmaceuticals and SNBL Announce Publication of …
Oct 8, 2024 For further information, please visit www.satsumarx.com. About SNBL Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research organization …See details»
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on …
Jun 15, 2023 please visit www.satsumarx.com. About SNBL Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) (TSE:2395) is a listed nonclinical contract research ... organization …See details»
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of …
5 days ago For further information, please visit www.satsumarx.com. About SNBL Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research organization …See details»
2024-10-30 | Satsuma Pharmaceuticals and SNBL Resubmits
Oct 30, 2024 For further information, please visit www.satsumarx.com. About SNBL. Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research …See details»
Satsuma Pharmaceuticals CEO and Key Executive Team - Craft
Satsuma Pharmaceuticals's Board Member is Ken Takanashi. Other executives include Heath Lukatch, Board Member; Michael Riebe, Board Member and 8 others. See the full leadership …See details»
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug …
Oct 31, 2024 For further information, please visit www.satsumarx.com. About SNBL. Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) (TSE:2395) is a listed contract research …See details»
Satsuma Pharmaceuticals and SNBL Announce Publication of …
Oct 8, 2024 Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 …See details»
Shannon Strom, PhD, R.A.C. | Satsuma Pharmaceuticals
Shannon began her career through a drug development fellowship with Cato Research, a specialty contract research organization, and then transitioned into medical writing and …See details»
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug …
Oct 30, 2024 For further information, please visit www.satsumarx.com. About SNBL. Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed contract research …See details»